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Introduction
Most individuals with familial predisposition to ovarian carcinoma carry a germline mutation in the BRCA1 gene. In spite of all the efforts aimed at unerstanding the normal function of the BRCA1 gene product during the last decade, the reason for the association between BRCA1 mutations and disease predisposition are still unclear. In particular, there is no good explanation for the site specificity of the cancers that develop in these individuals. Indeed, although the BRCA1 gene is expressed in most cell types, mutation carriers develop primarily breast and ovarian/fallopian tube tumors. We hypothesized that BRCA1 controls ovarian cancer predisposition in a cell non-autonomous manner, through a factor secreted by ovarian granulosa cells. The idea is that reduction in BRCA1 activity in granulosa cells results in changes in the secretion, by those cells, of one or several circulating or paracrine factors that influence the cell of origin of ovarian tumors. We tested this hypothesis by inactivating the Brca1 gene in mouse ovarian granulosa cells specifically. We had reported, in our initial grant application, that over 50% of the mice carrying this targeted gene knockout developed ovarian/tubal tumors morphologically very similar to human ovarian serous cystadenomas in strong support of our hypothesis. We proposed to elucidate the mechanism of tumor predisposition in this mouse model by identifying the signaling molecules downstream of Brca1 that control tumorigenesis (aim #1) and to test the hypothesis that tumor development in this animal model results from an effect of Brca1 on the epithelial cells lining the entire mullerian tract (aim #2). This latter hypothesis has important implications on the understanding of the exact site of origin of human ovarian epithelial tumors.
Body
The progress related to each task mentioned in the original statement of work is summarized below:
Task 1: Breed and genotype mice to support aims #1 and #2. According to our initial statement, this task was essentially meant to maintain our mouse colonies in order to secure enough mice to support the other tasks. This was continued during year 2, primarily in support of aim #2. We also continued to examine the phenotype of mutant versus wild type mice and, in that regard, expanded the number of wild type (control) mice examined in order to increase the strength of our argument. As of January 2006, 40 of 59 mutant mice developed cysts either in the ovary or uterus while only two of 56 littermate controls developed uterine cysts. The cysts seen in those two control mice were smaller and less numerous than those seen in mutant mice. We therefore maintain our earlier conclusion that targeted inactivation of Brca1 in our mouse model influences proliferation of epithelial cells along the entire mullerian tract. We reported these results and stated that conclusion in a manuscript that was under revision at the time of our last progress report, but has since been published in Current Biology (Curr Biol 15:561-565, 2005) . The potential impact of this work is underscored by the fact that it was featured in the News & View section of Nature, April 14, 2005 issue.
Given that humans with germline BRCA1 mutations are predisposed to breast carcinoma in addition to cancers of the mullerian tract, we also started examining the mammary glands of wild type and mutant animals. The number of mammary glands examined is still small, as we first needed to train ourselves at finding and examining this organ, especially since we wanted to examine older mice, where mammary glands are often atrophic and not readily seen. We examined the fourth mammary Normal ducts
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Fig. 1:
gland pair in eight mutant and eight wild type mice with ages ranging between 12 and 18 months. All mice used in this study were virgins. Mammary glands from three of the mutant mice showed dilated breast ducts filled with proteinaceous fluid alternating with areas showing small, inactive ducts. The remaining mutant and all wild type mice showed only s m a l l i n a c t i v e d u c t s . A representative section of dilated ducts from one mutant is shown in the photomicrograph shown in Fig.  1 . The present of such cysts is clearly abnormal and reminiscent of fibrocystic desease in humans. The fact that mutant mice develop abnormalities in the breast in addition to the reproductive tract argues strongly in favor of the relevance of our animal model to humans.
Task #2: Test specific candidate hormones for their potential regulation by BRCA1 in vivo. The original plan was to measure circulating levels of various hormones at specific stages of the estrous cycle, which we proposed to evaluate based on the color of the vaginal mucosa. It turned out that this method of determining the stage of the estrous cycle is very inaccurate and subjective. As indicated in our previous progress report, we therefore trained ourselves to determine the stage of the estrus cycle from cytological examination of vaginal lavages stained with Papanicoulou (PAP) stains. We took advantage of this method to expand this task. We reasoned that we should complement our studies aimed at measuring circulating hormone levels with studies aimed at comparing the length of each phase of the estrus cycle in wild type versus mutant mice. We had not proposed these studies in our initial application because we did not have the knowledge and technical expertise to do this at that time. We have since examined the length of the various phases of the cycle in a group of wild type and mutant 7-8 month old mice. We also collected serum samples from each mouse. The estrus cycle length was calculated based of daily examinations of vaginal smears over 2-3 weeks. The mice have almost reached the age of 14 months, our next time point. Our plan is to re-examine the mice at that age. The mice will then be sacrificed and their reproductive organs will be examined. We will therefore be able to correlate the presence or absence of ovarian and uterine tumors with estrus cycle abnormalities and circulating hormone levels obtained from 2 different time points. Although this experiment is not completed because we still need to examine and sacrifice the mice at 14 months, the results available so far show a statistically significant elongation of the diestrus and proestrus phases of the cycle in mutant mice as summarized in the following Tables:  493  2. The results of Table 1 and 2 revealed that the average combined length of diestrus + proestrus (corresponding to the follicular phase in human) was 2.9 in wild type mice compared to 5.1 in mutant mice (P = 0.03, t test). There was no significant difference in the average length of metestrus (corresponding to luteal phase in human) between the two groups. By the end of year 3, we should know whether mice with abnormal cycles are the ones most likely to develop cystic tumors. Although we have collected serum samples from the 7-8 month old mice used for this study, we have not measured hormone levels yet because we elected to wait until samples from the 14 months time point are collected in order to perform all measurements in parallel.
We repeated the above experiment with 3-4 month old mice, which we plan to re-examine at 7-8 months and 14 months. Again, serum samples will be collected and the mice will be sacrificed at the end of the study in order to determine whether mice with abnormal cycles are most likely to develop cysts in their reproductive tract. The results at 3-4 months are now available and confirm the findings of Table 1 and 2 that mutant mice have a longer cycle due primarily to an increase in the length of diestrus and proestrus. The length of the diestrus phase at 3-4 months was 4.2 +/-2.0 in mutant mice versus 2.3 +/-1.0 in controls (P = >04) and the length of proestrus was 2.5 +/-0.9 in mutant versus 1.5 +/-0.6 in controls (P = .02). We anticipate to publish the results in a high profile peer reviewed journal once this study is completed, focussing the discussion on the role of the ovulatory cycle on ovarian tumor predisposition.
Task #3: Test specific candidate hormones for their potential regulation by Brca1 in vitro.
The initial proposal was to remove both ovaries from one mutant mouse and one control mouse, harvest granulosa cells, and initiate several granulosa cell cultures per mouse in vitro. After ensuring purity of our cell cultures and verifying their authenticity, we would measure and compare the levels of hormones secreted in the conditioned medium in normal versus mutant mice. We have succeeded in obtaining cultures of granulosa cells as initially proposed. We were able to obtain primary cultures of such cells by using sterile needles to puncture ovarian follicles and aspirating the cell rich fluid with a syringe, followed by dispersing the cells and plating them in tissue culture dishes. We showed, in our previous progress report, that the cultured cells expressed mullerian inhibiting substance and developed a strategy to look at the consequences of various hormones of interest on Brca1 expression. Unfortunately, in spite of much effort, we were unable to obtain conclusive results because of a problem that we were not familiar with initially and that we had not anticipated. It turns out that once in culture, granulosa cells, whether from human or mice, differentiate and stop expressing receptors for steroid and gonadotropin hormones. We have contacted reproductive biologists, who were only able to confirm that this is a problem. Our next strategy, which is being pursued during the third year, is to treat mice with high levels of hormones in vivo and to look at Brca1 expression by immunohistochemistry and real time PCR in granulosa cells 24 hours post treatment. We realize that this is quite different than our original aim, but those changes in our approach were necessary and should provide us with information on the response of Brca1 to hormones of interest, which was our original intention.
Task s#4 and #5: Expression microarray analyses to compare gene expression in normal and mutant granulosa cells. We needed to modify our approach for the same reason quoted under "Task #3". Our initial strategy relied on the use of cultured granulosa cells isolated from wild type and mutant ovaries as starting material. Once we became familiar with the magnitude of the changes that granulosa cells undergo once put in culture, we realized that our proposed studies would have very little impact if carried out as initially proposed. In response, we now propose to use microdissected cells from frozen mutant and wild type mouse ovaries. This has in part become possible because of novel technologies that were not yet available to us at the time our grant application was first submitted. Affymetrix has developed chips allowing analysis not only of the 3'-end of mRNA species, but of all exons. The human chips (HuEx) have just been released and although it will be another few months before the murine chips (MuEx) are released, these are already available to us via the Early Access Program. There are several advantages to using these chips as opposed to the older U133 series. First, they evaluate an entire gene as opposed to its 3'-end and therefore provide exon level usage and expression data. Second, they are compatible with partly degraded DNA while success with the U133 series was dependent on the availability of intact, high molecular weight RNA. Finally and of great importance to this application, the HhuEx chips have been validated for studies using as little as one ng of RNA as starting material, making this technology readily applicable to cells microdissected from tissue sections. Indeed, if we consider that the average amount of total mRNA per cell to be around 0.1 ng, than using 200 cells per experiment, which is readily obtainable through laser capture microdissection, should provide us with more than sufficient material for our proposed analyses.
Our decision to use this novel technology is not only driven by the fact that we encountered unanticipated problems with our original approach. Even without these problems, we would probably have elected to change our strategy and use the all exon arrays for our proposed experiments in an effort to adapt to technological progress. It is increasingly clear that the 20,000 or so annotated mouse and human genes are in fact static representations of vastly more complex patterns of exon usage in different circumstances. The all exon arrays will allow analysis of both of gene expression (as a virtual gene or "metagene", representing averaged expression values over all consensus exons ascribed to that gene) and exon usage (by evaluation of expression of each exon linked to that gene). It will also be possible to detect aberrant expression of other exons and anonymous genes by data mining of the 1.4 million exons present on these arrays; only about half are accounted for by known gene sequences. Importantly, this includes non-coding RNAs such as micro RNAs and any other expressed RNA sequence found in public databases as of 2004.
Task #6: Comparing proliferation of specific mullerian-derived tissues and ovarian tissues in mutant versus normal mice. Our original plan was to compare the proliferation rate of various tissues of interest in the reproductive tract in normal and mutant mice. We made progress toward this goal during the second year by comparing cellular proliferation activity in the uterus of 5 wild type and 5 mutant mice at the diestrus ad estrus phases of the estrus cycle. Histological crosssections were taken from each horn at the junction between the proximal (closest to the ovary) and middle thirds. All mice were 3-4 months old. The sections were stained with antibodies against PCNA, a marker of cell cycle activity. A digital photomicrograph of representative areas of each uterus was taken under 40X objective and the total number of endometrial stromal cells showing either positive or negative nuclear staining for PCNA was determined. In accordance with the results shown in last year's progress report, there was a 50% increase in the average percentage of PCNA positive glandular epithelial cells in mutant mice, although there was great variation among the different samples, including one mutant sample that showed almost total lack of PCNA staining, and the results were not statistically significant. There were significant differences in the endometrial stroma. An average of 716 +/-60 stromal cells were examined in the 5 mutant mice and of 846 +/-154 cells in the 5 wild type mice. The percentage of PCNA positive stromal cells was 67.8 +/-6.7% in mutant compared to 36.1 +/-25% in wild type mice (P = .025, t test). This provides further support for the idea that measurable phenotypic differences exist between cells derived from the mullerian tract in wild type versus mutant animals in addition to raising interesting issues about the importance of epithelial-stromal interactions in the uterus. Given that a wild type Brca1 was expressed in the uterus of mutant animals, the results also provide additional support a cell non-autonomous mechanism. We have already set up experiments to examine other stages of the estrus cycle and plan to use other markers listed in the application.
Another set of experiments performed in year 2 investigated differences in cellular proliferation in the uterus of wild type versus mutant mice in animals synchronized with regard to their estrus cycles. In the experiment shown in Fig. 2 , two mutant mice and two wild type mice were inoculated with PMSG to stimulate follicular growth, followed 48 hours later by inoculation of hCG to induce ovulation. The mice were sacrificed 24 hours after receiving the latter hormone and the uteri were examined for PCNA immunoreactivity. The total number of glandular cells in the entire uterine sections was determined and the percentage of cells that were positive for PCNA was calculated. As shown in the figure, there were practically no glandular cells that were positive for this marker in the wild type mice. In contrast, an average of 24% of the glandular cells in mutant mice were positive. These results need to be regarded as preliminary until a larger number of mice is examined. However, the sharp differences between mutant and wild type animals are striking.
Fig. 2:
Task 7: Comparing proliferation of uterine cysts in mutant mice ovariectomized at specific time points. Although we have initiated these experiments, the results are not yet available because we want to wait until the mice are 14 months old before sacrificing them in order to evaluate their phenotype.
Key Research Accomplishments since last progress report
• We showed that mice carrying a mutant Brca1 in their granulosa cells have a longer estrus cycle due primarily to increases in he length of the diestrus and proestrus phases. This is interesting in light of extensive epidemiological data showing that continuous (uninterrupted) menstrual cycles in humans are associated with increased ovarian cancer risk. • We showed preliminary data suggesting that mice carrying a mutant Brca1 in their granulosa cells show increased cell proliferation in the endometrial stroma as well as in endometrial
Percentage of Total
Glandular Epithelial Cells that are PCNA Positive glandular epithelium, at least at specific phases of the estrus cycle. A similar increase in endometrial glandular proliferation was seen in mutant mice treated with Pregnant Mare Serum Gonadotropins (PMSG) compared to normal mice ttreated with the same dose of PMSG.
• We revised our strategy for our gene expression profiling studies (Task #4) and our studies on hormonal regulation by Brca1 (Task #3) in light of unanticipated problems with our original approach as well as in an effort to adapt to recent technological progress.
Reportable Outcomes
A manuscript describing our mouse model and arguing that Brca1 controls cancer predisposition in a cell non-autonomous manner was published in Current Biology (Curr Biol 15:561-565, 2005) . This manuscript was under review at the time of our last progress report. The potential impact of this work is underscored by the fact that it was featured in the News & View section of Nature, April 14, 2005 issue.
Since our last progress report, Dr. Dubeau was invited to present the work performed in the context of this grant in two symposia, including a symposium on "Ovarian Cancer: Prevention and detection of the Disease and its recurrence" held in Pittsburgh, PA in October 2005 and an International Conference on Ovarian cancer to be held in Crete (Greece) in June 2006. The official handout for the Pittsburgh symposium and the official abstract for the Crete symposium are appended.
Conclusions
Our results confirm the preliminary data presented in our initial grant application and continue to provide strong support, based on a novel experimental mouse model, for the idea that the reason why individuals with germline mutations in the BRCA1 gene are predisposed to ovarian cancer is that the ensuing decrease in BRCA1 gene dosage results in a disruption of normal cellular interactions between ovarian granulosa cells and the cells from which ovarian epithelial tumors originate. In other words, BRCA1 controls the secretion of one or several hormonal or paracrine factor(s) by granulosa cells that can influence ovarian tumor predisposition. We further characterized the phenotype of the mutant mice during the second year of this grant by showing that mutant mice have increased endometrial stromal and glandular proliferation at specific stages of their estrus cycle as well as following treatment with gonadotropin hormones. Our most significant progress during the second year was the demonstration that mutant mice have longer estrus cycles, due primarily to an increase in diestrus and proestrus, which correspond to the preovulatory phases of the human menstrual cycle characterized by unopposed estrogen stimulation. This is intriguing in light of the vast epidemiological data showing a strong correlation between menstrual cycle activity and increased risk of ovarian cancer.
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Response to reviewer's comments
The original progress report was modified in response to reviewer's comments and comply to specific requests. To facilitate review of this revised report, this section indicates, point by point, how each of the reviewer's concerns were addressed.
The PI listed invited seminar and symposia presentations of the work resulting from this project as Reportable Outcome but failed to append abstracts (with full details) as required by USAMRMC There were no official abstracts for the Pittsburgh meeting. However, an official handout containing the slides used during the presentation was given to all participants. I have appended this handout to the revised progress report. There was an official abstract that was part of the meeting material given to all participants at the Crete meeting. This abstract has also been appended. In retrospect, I realize that the seminar given at University of Virginia should not have been listed as reportable outcome because it was simply a lecture given in the context of a seminar series at this institution. There were no written documents released. I have deleted this seminar from the section on "Reportable Outcomes" in the revised report.
This reviewer recommends, at a minimum, a modification of the Statement of Work (SOW) and revised scope of the work A revised statement of work, which reflects the changes mentioned in the progress report under tasks 3-4, has been appended to the revised report. Task 5, which is a verification of the microarray data, will be performed based on data obtained from dissected granulosa cells as opposed to cultured granulosa cells. However, this task remains essentially the same as the original task 5.
In Task 4 the PI plans to microdissect frozen embryos and will use HuEX and MuEX chips for microarray analysis. This reviewer is uncertain if the proposed experiments will be done on human or mouse frozen embryos. The PI has not been granted approval to use human substances.
The only reason why the HuEx chip was mentioned in the original progress report was because this is the only exon array chip that was commercially available at the time of submission of the report and we wanted to make the point that this technology was available. Our plan all along has been to use the MuEx chip on mutant versus wild type mice. This chip has now been released and is available to us. We have modified the body of the progress report in the paragraph describing tasks #4 and #5 in order to clarify that our proposed studies will be done on mice. cyst was observed in a single case. Although the com-Granulosa cells also secrete mullerian inhibiting subplexity and cellular atypia levels seen in the solid comstance (MIS), a hormone that inhibits both the formaponent were compatible with a malignant process, the tion of female reproductive organs in male embryos malignant potential of this tumor remains unclear be-[8] and the proliferation of ovarian epithelial tumor cause it showed no evidence of either invasion of surcells [9, 10]. We tested this hypothesis by using the rounding structures or metastasis ( Figure 2D ). Renal Cre-lox system to inactivate the Brca1 gene in mouse cysts were also observed in two mutant mice. No abovarian granulosa cells. A truncated form of the Fsh normality was seen in any of 36 age-matched littermate receptor promoter [11] served as the Cre driver. Here, controls lacking Cre recombinase. we show that indeed, inactivation of the Brca1 gene in granulosa cells led to the development of cystic Evidence for a Cell-Nonautonomous Mechanism tumors in the ovaries and uterine horns. These tuof Tumor Induction mors carried normal Brca1 alleles, supporting the Our studies with the R26R reporter mouse (Figure 1 ) view that Brca1 may influence tumor development insuggested that rearrangement of the Brca1 gene in redirectly, possibly through an effector secreted by sponse to Fshr-Cre occurred primarily in ovarian granugranulosa cells.
losa cells, our intended target. That all tumors exhibited an epithelial morphology suggested that they were not Results derived from granulosa cells. Further support for this possibility came from findings that the tumor cells (1) Granulosa Cell Specificity of Truncated Fsh expressed keratins (Figure 3) , which are markers of epi-Receptor Promoter thelial cells, and (2) did not express mullerian inhibiting We verified the cell-type specificity of a truncated Fsh substance, a marker of granulosa cells (Figure 3) . The receptor promoter form shown previously to direct extumor cells also expressed estrogen (Figure 3) and propression exclusively in granulosa cells [11] . We crossed gesterone (not shown) receptor proteins, further supa transgenic mouse expressing the Cre recombinase porting the view that they were functionally similar to under the control of this promoter fragment with the human ovarian epithelial tumors.
ROSA26R Cre reporter mouse strain [12]. Examination
The conclusion that the tumors did not originate in of the pelvic organs of mice carrying the Cre driver and granulosa cells was also supported by the fact that they were often localized in the uterine horns, which do not contain granulosa cells. The possibility remained *Correspondence: ldubeau@usc.edu Although we did not examine breast tissue in Brca1 flox/flox;Fshr-cre mice, we note that ovulatory activity, amplified readily from all tissues examined with PCR primers specific for this allele, the only tissues from which is controlled largely by the activity of granulosa cells, is a well-established risk factor for breast cancer which the expected 640 bp product from the rearranged allele could be amplified were whole ovaries, in humans [14] . That mice lacking a functional Brca1 protein in their the site of granulosa cells, as well as one of four ovarian cysts that had been separated from the adjacent ova-granulosa cells developed lesions involving the uterine horns in addition to the ovaries is consistent with the ries with scissors under a dissecting microscope (Figure 4, bottom panel) . The weak amplification product observation that precancerous changes are frequently seen in the fallopian tubes of women who are asymp-obtained with primers specific for the rearranged allele (pair e-d) in this ovarian cyst most likely reflects the tomatic carriers of BRCA1 mutations [2-4]. This is also compatible with L.D.'s earlier suggestion that ovarian presence of admixed ovarian stroma, either in the cyst wall or in contaminating fragments of normal ovary. It epithelial tumors do not originate from the mesothelial layer lining the ovarian surface, the site favored by most is highly unlikely that this allele played a role in tumor development owing to its absence in most cystic tu-
authors, but from mullerian duct derivatives surrounding the ovary or abutting this organ [15]. mors examined. A fifth ovarian cyst, subjected to laser capture microdissection to ensure absence of admixed Most tumors that develop in individuals with germline BRCA1 mutations and show loss of heterozygosity at granulosa cells, did not contain the rearranged allele either in the lining epithelium or in the cyst wall (Figure the BRCA1 locus have retained the mutant allele [16-18], suggesting that BRCA1 may act as a classical tu-4, middle panel). We detected only the unrearraged allele in the epithelial lining of two additional uterine cysts mor suppressor. However, not all tumors that develop in this group of patients carry losses of heterozygosity examined after laser capture microdissection (not shown). at this locus [18], and there is little evidence for the notion that the wild-type allele in these tumors is silenced by epigenetic mechanisms [19]. In addition, a Discussion
number of observations suggest that total loss of BRCA1 activity does not promote, but interferes with Our results strongly support our hypothesis that inactivation of the Brca1 gene in granulosa cells acts cell-cellular growth. The small number of breast or ovarian cancer cell lines so far isolated that lack a functional nonautonomously by altering the activity of an effector that influences tumorigenesis in cells from which ovar-BRCA1 protein typically have long doubling times. Primary cultures derived from Brca1 − / − mouse embryos ian epithelial tumors originate. This conclusion is based It is possible that the Fshr promoter used in our studies is expressed in cells other than granulosa cells at levels undetectable with the R26R reporter mouse. Thus, non-granulosa cells may control ovarian and uterine tumorigenesis. However, we favor the hypothesis that it is the granulosa cells that act at a distance to control mullerian epithelial tumorigenesis via a mechanism regulated by Brca1. At least in reproductive organs, these cells appear to be the principal site of Brca1 inactivation. The idea that a specific effector released by granulosa cells and regulated by Brca1 influences tumor predisposition in the mullerian tract is both the simplest and biologically most attractive hypothesis that follows from our data. Another possibility is that an abnormal Brca1 expression might result in alterations in the dynamics of the estrus cycle. An example would be changes in the length of a specific phase of this cycle. Such changes, in turn, might influence tumor predisposition.
The finding that loss of Brca1 in mouse ovarian granulosa cells causes epithelial tumors in wild-type cells of the ovary and uterus raises the prospect that reduced levels of functional BRCA1 protein in humans carrying a germline BRCA1 mutation could lead to the development of cancer by modulating the ability of granulosa cells to act on distant target tissues. This hypothesis has important implications for the clinical management of individuals with a familial predisposition to ovarian tumors owing to germline BRCA1 mutations. Knowing the identity of the endocrine or paracrine factor(s) that mediates such actions at a distance could provide a new way to identify individuals predisposed to ovarian cancer and could also form the basis for novel strategies based on manipulations of the levels of the factor(s) in question and aimed at preventing ovarian cancer in individuals with familial predisposition to this disease.
Experimental Procedures Figure 2. Examples of Ovarian and Uterine Lesions Observed in Immunohistochemical Analyses
Mutant Mice The mouse monoclonal antibody against nonsquamous keratins Shown are gross photographs of ovarian (arrows in [A] and [B]) and was purchased from Chemicon International (Temecula, CA, MAB uterine (arrows in [E]) cysts and histological sections from ovarian 1611). The polyclonal goat antibody against mouse mullerian inhib-(C and D) and uterine (F-H) lesions. The ovarian tumor shown in (A)
iting substance was purchased from Santa Cruz Biotechnology was 80% cystic and 20% solid. Histological sections of both of (Santa Cruz, CA, catalog number sc-6886). Goat polyclonal antithese components are shown in (C) and (D), respectively. A bilocubodies against mouse estrogen receptor α and progesterone relar cyst on the external surface of a uterine horn is shown under ceptor proteins were purchased from Santa Cruz Biotechnology low and high magnification in panels (F) and (H), respectively. A  (catalog numbers sc-542 and sc-2018, respectively) Oncol. 72, 437-442.  16. Cornelis, R.S., Neuhausen, S.L., Johansson, O., Arason, A.,  Kelsell, D., Ponder, B.A., Tonin, P., Hamann, U., Lindblom, A. , and Lalle, P. (1995). High allele loss rates at 17q12-q21 in breast and ovarian tumors from BRCAl-linked families. The Breast Cancer Linkage Consortium. Genes Chromosomes  Cancer 13, 203-210.  17. Smith, S.A., Easton, D.F., Evans, D.G., and Ponder, B.A. (1992) .
Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat . Genet. 2,  128-131.  18. Neuhausen, S.L., and Marshall, C.J. (1994) . Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds. Cancer Res. 54, 6069-6072.  19. Esteller, M., Silva, J.M., Dominguez, G., Bonilla, F., Matias-Guiu, X., Lerma, E., Bussaglia, E., Prat, J., Harkes, I.C., Repasky, E.A., et al. (2000) . Genet. 12, 191-194.  22. Ouchi, M., Fujiuchi, N., Sasai, K., Katayama, H., Minamishima,  Y.A., Ongusaha, P.P., Deng, C., Sen, S., Lee, S.W., " (primer pair e-d, middle panel) was sequenced, confirming that it represents a nonspecific product. The 647 bp product from normal ovaries with the same primers was also sequenced and shown to be authentic. Griswold, M.D., Heckert, L., and Linder, C. (1995) . The molecular biology of the FSH receptor. J. Steroid Biochem. Mol. Biol.  53, 215-218.  12. Soriano, P. (1999) . Generalized lacZ expression with the ROSA26 cre reporter strain. Nat . Genet. 21, 70-71.  13. Xu, X., Wagner, K.-U., Larson, D., Weaver, Z., Li, C., Ried, T.,  Hennighausen, L., Wynshaw-Boris, A., and Deng, C.-X. (1999) . Conditional mutation of BRCA1 in mammary epithelial cells results in blunted ductal morphogenesis and tumor formation. Nat . Genet. 22, 37-43.  14. Kelsey, J.L., and Bernstein, L. (1996) was avoided by knocking out this gene in granulosa cells specifically ! Mouse carrying mutant alleles of BRCA1 in their granulosa cells had morphologically normal ovarian follicles and were fertile, but developed benign and malignant epithelial ovarian tumors as well as extraovarian cysts in their mullerian tract ! Alterations in interactions between granulosa cells and the cell of origin of ovarian epithelial tumors may be the key to familial ovarian cancer predisposition in individuals carrying germline BRCA1 mutations.
11.
SIGNIFICANCE
" A better understanding of the normal interactions between ovarian granulosa cells and the cell of origin of ovarian epithelial tumors may lead to novel strategies for the identification of individuals at risk and for ovarian cancer prevention. " The results support the hypothesis that ovarian epithelial tumors are of mullerian origin, which is important for the understanding of their precursor lesions and for the development of effective screening strategies for their early detection. 
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Title: BRCA1 INDUCED OVARIAN ONCOGENESIS
Louis Dubeau
University of Southern California Keck school of Medicine USC/Norris Comprehensive Cancer Center
Women with germline mutations in BRCA1 have a 40% risk of developing ovarian cancer by age 70 and are also predisposed to cancers of the fallopian tubes and breast. Although some observations are supportive of the currently favored notion that BRCA1 functions as a classical tumor suppressor gene, others are inconsistent with this notion. Given that ovulatory activity is a strong risk factor for sporadic ovarian cancer, we hypothesized that reduced BRCA1 expression might predispose to gynecological cancers indirectly by influencing ovarian granulosa cells. These cells secrete sex steroids that control the ovulatory cycle and influence the growth of ovarian epithelial tumors. We tested this hypothesis by using the Cre-lox system to inactivate the Brca1 gene in mouse ovarian granulosa cells. A truncated form of the FSH receptor promoter served as the Cre driver in order to achieve such tissue specificity. Indeed, inactivation of the Brca1 gene in granulosa cells led to the development of benign cystic tumors in the ovaries and uterine horns in approximately one third of the mutant mice. The mutant mice also developed epithelial cysts in their mammary glands. These tumors were of epithelial origin and carried normal Brca1 alleles, supporting the view that Brca1 influenced their development indirectly, through an effector secreted by granulosa cells. The fact that the cystic tumors were not confined to the ovaries, but involved the entire mullerian tract, is also consistent with the view that ovarian tumors are not of mesothelial origin, but are derived from the mullerian tract. We measured the length of each phase of the estrus cycle in a group of mutant and wild type mice at 3-4 months and 7-8 months of age. In both age groups, there was a significant increase in the length of proestrus, which corresponds to the follicular phase of the human menstrual cycle. We suggest that the increased cancer predisposition seen in individuals carrying a germline BRCA1 mutation is due, at least in part, to reduced levels of BRCA1 expression in granulosa cells. This, in turn, may lead to alterations in the length of the follicular phase of the menstrual cycle and ensuing increased unopposed estrogen stimulation as well as, perhaps, to disruption of additional interactions between granulosa cells and mullerian epithelial cells resulting in promotion of neoplastic transformation.
Task #1: Breed and genotype mice to support aims #1 and #2. Breed FSHR/cre mice with floxed BRCA1 mice and perform genotyping analyses of offspring. Mice with homozygous rearrangements of the BRCA1 gene will be used as "mutant" mice. Mice with no rearrangement will be used as "control" mice. Mice with heterozygous rearrangements will be discarded. A total of 222 mice will be needed to support aims #1 and of 258 to support aim #2. Period: months 1-36. Outcome: enough control and mutant mice will be generated to support our proposed studies.
Task #2: Test specific candidate hormones for their potential regulation by BRCA1 in vivo (aim #1). Draw 200 microliters of blood from 25 mutant mice and from 25 control mice10-12 months of age on the second day of the estrus cycle (determined from examination of color changes on the vaginal mucosa). Collect serum and send to Dr. Stanczyk's lab for measurement of levels of estradiol, estrone, and progesterone. Keep 25 microliters of each serum sample for measuring MIS by ELISA in Dr.Dubeau's laboratory. Sacrifice mice after blood is collected and examine ovaries for MIS levels by immunohistochemistry. (months 1-3, repeat during months 4-7). Period: months 1-3, repeat during months 4-7. Outcome: the consequences of BRCA1 mutation on specific hormones of interest in mice will be determined.
Task #3: Test specific candidate hormones for their potential regulation by BRCA1 in vivo. Inoculate 3-4 month old wild type mice obtained from same litters as our Brca1 knock out mice with PMSG followed, 48 hours later, by inoculation of either hCG or vehicle control. Sacrifice the mice and examine the ovaries for expression of Brca1 by immunohistochemistry and real-time RT-PCR. Five mice will be used in each group. This study will be repeated a second time to ensure reproducibility. Period: months 30-36. Outcome: Knowledge of the effects of reproductive hormones on Brca1 expression, used in conjunction with the observation that loss of Brca1 activity in granulosa cells predisposes to ovarian tumor development, will shed light on possible explanations for the well-established link between the menstrual cycle and ovarian cancer predisposition.
Task #4: Expression microarray analyses to compare gene expression in normal and mutant granulosa cells. Examine vaginal cytology in mutant and littermate controls at 3-4 months and 7-8 months in order to identify animals at the proestrus phase of their cycle and sacrifice 5 mice in each group at this phase of the cycle. Obtain frozen sections of the ovaries and use laser capture microdissection to microdissect about 500 granulosa cells from secondary ovarian follicles. Extract total RNA from each ovary and pool RNA samples from each group. Give samples to Genomics Core Facility for preparation of cDNA, hybridization to MuEx expression microarray chips, and data analysis. Repeat once. Period: months 30-36. Outcome: Comprehensive knowledge of the signaling pathways affected by inactivation of BRCA1 in granulosa cells will be acquired. This will provide independent verification of the conclusions from tasks #2 and #3 and will increase our understanding of the consequences of BRCA1 mutations.
Task #5: Verification of microarray data. Gene products of interest thought to be upregulated or downregulated in mutant mice based on microarray data will be analyzed either by quantitative RT-PCR (using a TaqMan 7700 instrument available in Dr. Dubeau's lab) or by immunohistochemistry and western blotting (depending on availability of suitable antibodies) in cultured normal versus mutant granulosa cells from 10-12 week old mice or in sections of ovarian tissue. If necessary due to lack of suitable alternative methods, in situ hybridization will be used. We anticipate that up to gene products will be tested during the course of he grant. Period: months 33-36. Outcome: predictions from task #4 will be verified.
Task #6: Comparing proliferation of specific mullerian-derived tissues and ovarian tissues in mutant versus normal mice (aim #2). Ovaries from 5 normal mice and from 5 mutant mice will be analyzed for histone-3 phosphorylation at 1, 2, 3, 6, and 12 months of age. Number of positive cells in endometrium at the proximal, mid, and distal ends of the uterine horns, rete ovarii, ovarian follicles (pre-and post-estrus), ovarian stroma, and ovarian surface epithelium will be quantitated and compared in both groups. Period: year 1, repeat in years 2 and 3. Outcome: The spectrum of tissues affected by BRCA1 mutations will be known, providing insights into the nature of the cell of origin of ovarian epithelial tumors and increasing our understanding of the mechanisms responsible for ovarian cancer predisposition in individuals carrying BRCA1 mutations.
Task #7: Comparing proliferation of uterine cysts in mutant mice ovariectomized at specific time points (aim #2). Mice will be ovariectomized at 1, 2, 6, and 12 months of age (5 mice will be obtained for each age group) and the number of cysts on the external uterine surface as well as cell proliferation (evaluated based on histone-3 phosphorylation) in the epithelial cells lining the cysts will be measured at 12 months of age.
Period: year 1, repeat in years 2 and 3. Outcome: we will know whether the effects of BRCA1 alterations are cumulative over long time periods or are most important at specific time points such as when mice reach sexual maturity; we will also learn about the reversibility of the changes associated with BRCA1 mutations.
Task #8: Collection of serum samples from normal women and BRCA1 carriers (aim #3). Serum samples from thirty 25-39 year old BRCA1 carriers and 30 matched controls will be collected by Dr. John Hopper and shipped to us. Period: years 1-2. Outcome: material needed for experiments proposed in aim #3 will be available.
Task #9: Measurement of MIS and sex steroid hormones in serum of normal and BRCA1 carrier women (aim #3). Measurement of estradiol, estrone, and progesterone levels will be done in the laboratory of Dr. Stanczyk. Measurements of MIS levels will be done by ELISA in Dr.Dubeau's laboratory. Period: year 3. Outcome: our hypothesis that women with germline BRCA1 mutations have altered levels of either MIS or of MIS:sex steroid hormone ratios will be tested.
